These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25918198)

  • 1. Benzodiazepine in a urine specimen without drug metabolites.
    Kampfrath T; Peng P; Vairavan V; Lee D
    Lab Med; 2015; 46(2):164-7. PubMed ID: 25918198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KIMS, CEDIA, and HS-CEDIA immunoassays are inadequately sensitive for detection of benzodiazepines in urine from patients treated for chronic pain.
    Darragh A; Snyder ML; Ptolemy AS; Melanson S
    Pain Physician; 2014; 17(4):359-66. PubMed ID: 25054395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limitations of EMIT benzodiazepine immunoassay for monitoring compliance of patients with benzodiazepine therapy even after hydrolyzing glucuronide metabolites in urine to increase cross-reactivity: comparison of immunoassay results with LC-MS/MS values.
    Dixon RB; Floyd D; Dasgupta A
    Ther Drug Monit; 2015 Feb; 37(1):137-9. PubMed ID: 25004136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of the diagnostic accuracy of liquid chromatography-tandem mass spectrometry versus immunoassay drug testing in pain patients.
    Pesce A; Rosenthal M; West R; West C; Crews B; Mikel C; Almazan P; Latyshev S
    Pain Physician; 2010; 13(3):273-81. PubMed ID: 20495592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of the accuracy of benzodiazepine testing in chronic pain patients utilizing immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing.
    Manchikanti L; Malla Y; Wargo BW; Fellows B
    Pain Physician; 2011; 14(3):259-70. PubMed ID: 21587329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical impact of a false-positive urine cocaine screening result on a patient's pain management.
    Kim JA; Ptolemy AS; Melanson SE; Janfaza DR; Ross EL
    Pain Med; 2015 Jun; 16(6):1073-6. PubMed ID: 24138673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic monitoring of benzodiazepines in the management of pain: current limitations of point of care immunoassays suggest testing by mass spectrometry to assure accuracy and improve patient safety.
    Mikel C; Pesce AJ; Rosenthal M; West C
    Clin Chim Acta; 2012 Aug; 413(15-16):1199-202. PubMed ID: 22484396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzodiazepines identified by capillary gas chromatography-mass spectrometry, with specific ion screening used to detect benzophenone derivatives.
    Jones CE; Wians FH; Martinez LA; Merritt GJ
    Clin Chem; 1989 Jul; 35(7):1394-8. PubMed ID: 2667799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary screening for alprazolam, triazolam, and their metabolites with the EMIT d.a.u. benzodiazepine metabolite assay.
    Fraser AD
    J Anal Toxicol; 1987; 11(6):263-6. PubMed ID: 3323671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of oral fluid in compliance monitoring of opioid medications.
    Conermann T; Gosalia AR; Kabazie AJ; Moore C; Miller K; Fetsch M; Irvan D
    Pain Physician; 2014; 17(1):63-70. PubMed ID: 24452646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced urine toxicology testing.
    Tenore PL
    J Addict Dis; 2010 Oct; 29(4):436-48. PubMed ID: 20924879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity of an opiate immunoassay for detecting hydrocodone and hydromorphone in urine from a clinical population: analysis of subthreshold results.
    Bertholf RL; Johannsen LM; Reisfield GM
    J Anal Toxicol; 2015; 39(1):24-8. PubMed ID: 25288720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection Times of Diazepam, Clonazepam, and Alprazolam in Oral Fluid Collected From Patients Admitted to Detoxification, After High and Repeated Drug Intake.
    Nordal K; Øiestad EL; Enger A; Christophersen AS; Vindenes V
    Ther Drug Monit; 2015 Aug; 37(4):451-60. PubMed ID: 25549207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the NexScreen and DrugCheck Waive RT urine drug detection cups.
    Lin CN; Nelson GJ; McMillin GA
    J Anal Toxicol; 2013; 37(1):30-6. PubMed ID: 23144203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS).
    Manchikanti L; Malla Y; Wargo BW; Cash KA; Pampati V; Damron KS; McManus CD; Brandon DE
    Pain Physician; 2010; 13(1):E1-E22. PubMed ID: 20119473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benzodiazepine screening using EMIT II and TDx: urine hydrolysis pretreatment required.
    Meatherall R
    J Anal Toxicol; 1994; 18(7):385-90. PubMed ID: 7861751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First experience with the REMEDi HS urine benzodiazepine assay.
    Musshoff F; Madea B
    Clin Chem Lab Med; 1998 Oct; 36(10):803-8. PubMed ID: 9853809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary screening for adinazolam and its major metabolites by the Emit d.a.u. and FPIA benzodiazepine assays with confirmation by HPLC.
    Fraser AD; Isner AF; Bryan W
    J Anal Toxicol; 1993; 17(7):427-31. PubMed ID: 8309217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitation of benzodiazepines in blood and urine using gas chromatography-mass spectrometry (GC-MS).
    Goldberger BA; Chronister CW; Merves ML
    Methods Mol Biol; 2010; 603():75-87. PubMed ID: 20077061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substance abuse and pregnancy: "we have a problem".
    Hill WC
    Clin Obstet Gynecol; 2013 Mar; 56(1):88-90. PubMed ID: 23314711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.